NC
APLS

nVerses Capital’s Apellis Pharmaceuticals APLS Stock Holding History

nVerses Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,800
Closed -$107K – 991
2024
Q2 		$107K Buy
2,800
+2,100
+300% +$95.1K 0.06% 427
2024
Q1 		$41.1K Buy
+700
New +$44.6K 0.1% 309

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

nVerses Capital's APLS Position: Q3 2024 in Review

nVerses Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 2,800 shares — an estimated $107K sold.

nVerses Capital first reported a position in APLS in Q1 2024 and held it in 2 quarters. The position peaked at $107K in Q2 2024. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • nVerses Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 2,800 Apellis Pharmaceuticals shares in Q3 2024, an estimated $107K.
  • nVerses Capital first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Apellis Pharmaceuticals position peaked at $107K in Q2 2024.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.